Despite Ocrelizumab Infection Risk, Roche Sees Multiple Sclerosis Opportunity
This article was originally published in The Pink Sheet Daily
Executive Summary
Anti-CD20 molecule's future in RA was dashed by high infection risk, but Roche says the safety profile of ocrelizumab could be better in MS patients.